Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q3 EPS of ($0.37), $0.15 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $43 thousand versus the consensus estimate of $14.46 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.